@article{muszbek_cost-utility_2021,
	title = {Cost-utility analysis of selective internal radiation therapy with {Y}-90 resin microspheres in hepatocellular carcinoma},
	volume = {17},
	issn = {1744-8301},
	doi = {10.2217/fon-2020-1004},
	abstract = {Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials \& methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25\%) and good liver function (albumin-bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.},
	language = {eng},
	number = {9},
	journal = {Future Oncology (London, England)},
	author = {Muszbek, N. and Remák, E. and Evans, R. and Brennan, V.K. and Colaone, F. and Shergill, S. and Mullan, D. and Ross, P.J.},
	month = mar,
	year = {2021},
	keywords = {cost–effectiveness, decision models, hepatocellular carcinoma, microspheres},
	pages = {1055--1068},
}

{"_id":"5eAKpdHMnDgp7FoMN","bibbaseid":"muszbek-remk-evans-brennan-colaone-shergill-mullan-ross-costutilityanalysisofselectiveinternalradiationtherapywithy90resinmicrospheresinhepatocellularcarcinoma-2021","authorIDs":[],"author_short":["Muszbek, N.","Remák, E.","Evans, R.","Brennan, V.","Colaone, F.","Shergill, S.","Mullan, D.","Ross, P."],"bibdata":{"bibtype":"article","type":"article","title":"Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma","volume":"17","issn":"1744-8301","doi":"10.2217/fon-2020-1004","abstract":"Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials & methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25%) and good liver function (albumin-bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.","language":"eng","number":"9","journal":"Future Oncology (London, England)","author":[{"propositions":[],"lastnames":["Muszbek"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Remák"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Evans"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Brennan"],"firstnames":["V.K."],"suffixes":[]},{"propositions":[],"lastnames":["Colaone"],"firstnames":["F."],"suffixes":[]},{"propositions":[],"lastnames":["Shergill"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Mullan"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Ross"],"firstnames":["P.J."],"suffixes":[]}],"month":"March","year":"2021","keywords":"cost–effectiveness, decision models, hepatocellular carcinoma, microspheres","pages":"1055–1068","bibtex":"@article{muszbek_cost-utility_2021,\n\ttitle = {Cost-utility analysis of selective internal radiation therapy with {Y}-90 resin microspheres in hepatocellular carcinoma},\n\tvolume = {17},\n\tissn = {1744-8301},\n\tdoi = {10.2217/fon-2020-1004},\n\tabstract = {Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials \\& methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25\\%) and good liver function (albumin-bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.},\n\tlanguage = {eng},\n\tnumber = {9},\n\tjournal = {Future Oncology (London, England)},\n\tauthor = {Muszbek, N. and Remák, E. and Evans, R. and Brennan, V.K. and Colaone, F. and Shergill, S. and Mullan, D. and Ross, P.J.},\n\tmonth = mar,\n\tyear = {2021},\n\tkeywords = {cost–effectiveness, decision models, hepatocellular carcinoma, microspheres},\n\tpages = {1055--1068},\n}\n\n","author_short":["Muszbek, N.","Remák, E.","Evans, R.","Brennan, V.","Colaone, F.","Shergill, S.","Mullan, D.","Ross, P."],"key":"muszbek_cost-utility_2021","id":"muszbek_cost-utility_2021","bibbaseid":"muszbek-remk-evans-brennan-colaone-shergill-mullan-ross-costutilityanalysisofselectiveinternalradiationtherapywithy90resinmicrospheresinhepatocellularcarcinoma-2021","role":"author","urls":{},"keyword":["cost–effectiveness","decision models","hepatocellular carcinoma","microspheres"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://api.zotero.org/groups/2370791/items?key=xZUdkZVhlhTAvt1X1CRQzNcj&format=bibtex&limit=100","creationDate":"2021-03-10T13:27:05.964Z","downloads":8,"keywords":["cost–effectiveness","decision models","hepatocellular carcinoma","microspheres"],"search_terms":["cost","utility","analysis","selective","internal","radiation","therapy","resin","microspheres","hepatocellular","carcinoma","muszbek","remák","evans","brennan","colaone","shergill","mullan","ross"],"title":"Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma","year":2021,"dataSources":["D2Q39xf6WKbfdGeLv","LiQPGJg2JYtcSm8X3"]}